An observational study in Neuromuscular Diseases, sponsored by Hospices Civils de Lyon. Completed at 5 sites in France. Open to participants aged 5 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-08-14.
Sponsored by Hospices Civils de Lyon · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Neuromuscular Diseases with a site in France — 14 open to participants now, 17 under way, 2 of them phase 3. Neuromuscular Diseases · France.
Among the 84 studies in Neuromuscular Diseases with a site in France, this one is the 12th largest by enrollment of the 36 observational ones that give a count, is one of 5 that started in 2018, is one of 36 observational ones, and was the 43rd registered.
361 studies on the registry are indexed under Neuromuscular Diseases; 97 are open to participants now.
Browse Neuromuscular Diseases studies →14 of the 84 studies in Neuromuscular Diseases with a site in France are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in France, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
Association APPROCHE · Sites in France
Ages 18+
University Hospital, Clermont-Ferrand · Sites in France
Ages 2+ · Healthy volunteers
University Hospital, Angers · Sites in France
Ages 6–17
AstraZeneca · Sites in France, United States, Canada and 7 more countries
Ages 18–70
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 70 Neuromuscular Diseases studies recruiting now, 39 (56%) set no upper age limit and 23 (33%) stop at 75 or younger; 36 take children under 18; 16 take healthy volunteers.
This study: 5 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 10
First in 2006; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 72 across 144 observational studies indexed under Neuromuscular Diseases.
Median enrollment 31 across the 48 interventional studies, 73 across the 36 observational. Of the 54 that completed or were terminated, 8 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 84 have an industry lead sponsor. The 10 most frequent:
Hospices Civils de Lyon is the lead sponsor of 1,867 studies on the registry; 448 are open to participants now.
Hospices Civils de Lyon has 5 studies filed under Neuromuscular Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Neuromuscular Diseases with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06249412Groupe Hospitalier du HavreThe Importance of Positive Expiratory Pressure Associated With the In-exsufflator in ALS Patients | 2026-12-01 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT07591779University Hospital, LimogesPhysical Activity Level at Home in CMT1A Patients: Wearable Sensor Assessment | 2027-04-15 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies in Neuromuscular Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Motor Function Measure (MFM) is a validated tool assessing the motor function of neuromuscular patients constituted of 32 items. Despite standardized Motor Function Measure (MFM) training sessions, there is still an inter-individual variability in the items' scoring procedure, depending for example on the subjectivity of the therapist.
Among the 32 items of the MFM, 3 currently require the use of a paper, and could be automated by using a digital tablet. It is the item 18 where the patient traces the edge of a Compact Disc, item 19 requiring to draw loops inside a frame and item 22 requiring to place a finger on each standardized cases. The reproducibility of these 3 items could be improved with the use of a digital tablet and the development of a software allowing to computerize the scoring procedure. The second interest is to implement directly the MFM data in the MFM base.
The hypothesis is that the difference of scoring of these 3 items between digital tablet versus paper completion is enough low to use indifferently each completion in patients with a neuromuscular disease.
Patients with neuromuscular disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will complete his Motor Function Measure in the usual way, except items 18, 19 and 22 which will be completed twice: once using conventional material and once on a digital tablet. The order of completion between conventional material or digital tablet will be allocate randomly.
Comparison scoring between items completed using conventional material or on a digital tablet.
The comparison of scores between usual test (paper) versus digital tablet test, for the item 18, 19 and 22 of the Motor Function Measure.
Time frame: 1 day
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2018 to primary completion in Nov 2018, 8 months.
Of 64 non-industry observational studies under Neuromuscular Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 114. This study's 8 months is below that.
Counting every sponsor, half of 70 studies reached it within 37 months; a quarter within 12 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.